key: cord-0698882-izwwn34t
authors: Wu, Ming; Zou, Zhi-ye; Chen, Yan-hong; Wang, Conglin; Feng, Yongwen; Liu, Zhi-feng
title: Severe COVID-19-associated sepsis is different from classical sepsis induced by pulmonary infection with carbapenem-resistant klebsiella pneumonia (CrKP)
date: 2021-11-15
journal: Chin J Traumatol
DOI: 10.1016/j.cjtee.2021.11.001
sha: 8e4bc009023158b6bb98b1d8f27c0c54fed3409c
doc_id: 698882
cord_uid: izwwn34t

PURPOSE: COVID-19 is also referred to as a typical viral septic pulmonary infection by 2019-nCoV. However, little is known regarding its characteristics in terms of systemic inflammation and organ injury, especially compared with classical bacterial sepsis. This article aims to learn the clinical characteristics and prognosis between COVID-19-associated sepsis and classic bacterial-induced sepsis. METHODS: In this retrospective cohort study, septic patients with COVID-19 in the intensive care unit (ICU) of a government-designed therapy center in Shenzhen, China between Jan 14, 2020 and Mar 10, 2020, and septic patients induced by carbapenem-resistant klebsiella pneumonia (CrKP) admitted at the ICU of the Second People’s Hospital of Shenzhen, China between Jan 1, 2014 and Oct 30, 2019, were enrolled. Demographic & clinical parameters including comorbidities, critical illness scores, treatment, and laboratory data, as well as prognosis were compared between the two groups. Risk factors for mortality and survival rate were analyzed using multivariable logistic regression and survival curve. RESULTS: A total of 107 patients with COVID-19 and 63 patients with CrKP were enrolled. A direct comparison between the two groups demonstrated more serious degrees of primary lung injury following 2019-nCoV infection (indicated by lower PaO(2)/FiO(2)) but milder systemic inflammatory response, lower sequential organ failure assessment (SOFA) score and better functions of the organs like heart, liver, kidney, coagulation, and circulation. However, the acquired immunosuppression presented in COVID-19 patients was more severe, which presented as lower lymphocyte counts. Moreover, the proportion of COVID-19 patients treated with corticosteroid therapy and extracorporeal membrane oxygenation was larger compared with CrKP patients who required less invasive mechanical ventilation. The incidence of hospitalized mortality and length of ICU stay and total hospital stay were also lower or shorter in viral sepsis. Similar results were obtained after being adjusted by age, gender, comorbidity and PaO2/FiO2. Lymphocytopenia and high acute physiology and chronic health evaluation II (APACH II) scores were common risk factors for in-hospital death. While the death cases of COVID-19 sepsis mostly occurred at the later stages of patients’ hospital stay. CONCLUSION: Critical COVID-19 shares clinical characteristics with classical bacterial sepsis, but the degree of systemic inflammatory response, secondary organ damage and mortality rate are less severe. However, following 2019-nCoV infection, the level of immunosuppression may be increased and thus induce in more death at the later stage of patients’ hospital stay.

Sepsis is a severe clinical syndrome, defined as the host body's dysregulated response to infection, which leads to life-threatening organ dysfunction. Sepsis is classically understood to be the result of bacterial infections, but the pathogenic microorganisms may also be viral, fungal, or other pathogens. 1, 2 However, sepsis caused by a virus or fungus is rarely reported, and there is a lack of clinical comparative data regarding the clinical characteristics and prognosis between sepsis caused by viral and classical bacterial infections. 2, 3 COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, 2019-nCoV). 4 Between December 2019 and October 28, 2021, there were more than 125,763 people infected with 2019-nCoV, with 5,696 deaths in China, and more than 245 million infections.

Globally, 4,984,415 people have died, including a large number of health workers, which makes COVID-19 one of the most serious problems for all health staff and researchers. 5, 6 COVID-19 has also been suggested to be a typical viral septic pulmonary infection with 2019-nCoV, which causes systemic inflammation and immune response dysregulation, potentially leading to multi-organ dysfunction and death. 7 The pathophysiology of sepsis is the dysregulation of inflammation and immune response after an infection, while classic bacterial sepsis is primarily characterized by excessive inflammation and acquired immunosuppression. Excessive inflammation includes the activation of a large number of innate immune cells and the release of a variety of inflammatory mediators, causing an inflammatory "storm" that impacts organs and may lead to multiple organ dysfunction syndrome (MODS). While immunosuppression is mostly attributed to the apoptosis and depletion of lymphocytes, including CD4+, CD8+ and B lymphocytes. 1, 8 A similar process of inflammation and immune changes has been suggested for viral sepsis, which can also lead to a delay in virus clearance, further aggravate viral infection and even the progression of sepsis by secondary bacterial infection. 9, 10 It has been reported that COVID-19 can also cause an inflammatory storm characterized by an increase in a variety of inflammatory mediators, including IL-6, and immunosuppression, which is characterized by obtained via direct communication with attending doctors. All data were confirmed by three physicians.

A confirmed case of COVID-19 was defined as a positive result using a real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay of pharyngeal swab specimens. COVID-19 was determined to be severe or critical as defined by the 7 th Chinese national guidelines for COVID-19. 15 Discharges criteria included patients being negative two times at a 24-h interval based on results from an RT-PCR assay of a pharyngeal swab specimen. A confirmed case of CrKP pneumonia was defined as a CrKP positive result on microbial cultivation from alveolar lavage or sputum culture with symptoms and signs of lung that cannot be explained by other causes.

The primary outcome was the in-hospital mortality (28-day and 60-day) and the secondary outcomes including clinical features and interventions.

The categorical data were summarized as numbers and percentages, and inter-group comparisons were performed using χ 2 test or Fisher's exact test. Continuous variables were expressed as the arithmetic mean and standard deviation (SD) or as the median and interquartile range, depending on the presence of a gaussian distribution. Continuous data with Gaussian distribution were compared using the Student's t test or one-way ANOVA; for those with a non-Gaussian distribution, the Wilcoxon rank-sum test was used.

Univariate analysis and multivariable logistic regression with a forced entry method was used to identify risk factors with a crude model and fully adjusted model: odds ratio (OR) and 95% confidence interval levels (95% CI). The 28-day and 60-day survival analysis were performed using Kaplan-Meier (K-M) There was a significant difference in immune and organ function in patients with COVID-19, presented as lower lymphocyte count (0.810 9 /L vs. 0.910 9 /L), total bilirubin (µmol/L, 12.5 vs. 15 (Table 3 ). Further analysis of the survival curve within 28 days and 60 days also showed that death from the CrKP often occurred in early stage, while death from the COVID-19 were mostly in the later stage ( Fig. 2 and 3 ). J o u r n a l P r e -p r o o f 

In order to confirm the clinical features and interventions associated with in-hospital mortality between patients with COVID-19 sepsis and those with CrKP sepsis, a multivariable logistic regression analysis was 

In the survivors group, compared to patients with CrKP, the patients with COVID-19 manifested as lower lymphocytes (0. (Table 6 ). 

This study compared the clinical features and prognosis between COVID-19-associated sepsis and classical bacterial sepsis. Results demonstrated that although the degree of primary lung injury caused by 2019-nCoV infection was more serious (indicated by lower PaO2/FiO2) than of patients with CrKP, the systemic inflammatory response was milder, SOFA score was lower, and organ function damage, such as the heart, liver, kidney, coagulation, and circulation were less severe. Meanwhile, the acquired immunosuppression was more severe, indicated by lower lymphocyte counts. 16 Moreover, the proportion of corticosteroid therapy and ECMO support in patients with COVID-19 was even higher, while the use of CRRT and invasive mechanical ventilation was lower, compared with CrKP patients. The hospitalized mortality, ICU and total length of hospital stay were also lower/shorter than that in patients with viral sepsis, J o u r n a l P r e -p r o o f and similar results were obtained after being adjusted for age, gender, and PaO2/FiO2. Lymphocytopenia and high APACH II scores were common risk factors for the in-hospital mortality, and the death due to COVID-19 sepsis occurred mostly at the later stages of hospitalization. These results provided a reference for improved understanding of 2019-nCoV infection and possible treatment measures.

Since CrKP is similar to COVID-19 with characteristics that may lead to systemic sepsis, we compared the characteristics of viral sepsis caused by 2019-nCoV with simple pulmonary CrKP infection. In order to eliminate selection bias, this study included all patients who were admitted to the ICU within the study time period. Firstly, the two study groups were similar from the primary infection, and pulmonary function in patients with COVID-19 is worse than that of CrKP, which is similar to the severe pulmonary damage caused by 2019-nCoV in the postmortem examination. 17, 18 2019-nCoV can directly invade type II alveolar epithelial cells, causing an inflammatory storm characterized by the increase of inflammatory mediators such as IL-6. Inflammatory cell infiltration by cells such as mononuclear phagocyte system, neutrophils, and lymphocytes, may lead to ARDS characterized by massive necrosis, exudation, and hyaline membrane formation of alveolar cells. 19, 20 This is similar to bacterial pulmonary infection, but there are also differences.

Gram-negative bacteria also infect local bronchial or alveolar epithelium, and then release a large number of inflammatory mediators such as IL-6 under the action of bacterial endotoxin lipopolysaccharide. This is accompanied by the infiltration of neutrophils and macrophages, resulting in cell necrosis, exudation, and hyaline membrane degeneration, which may then develop to ARDS. 21, 22 However, the difference is that the bacterial infection is characterized by massive exudation (showing a large amount of purulent sputum and high lung water value), intensive inflammation and tissue consolidation as local manifestations, and then the infection will gradually spread to the whole lung. In the virus sepsis the evolution of inflammation was slower, the inflammatory exudation was less, but the cellulose-like exudation and cell necrosis were more apparent. 19, 20 This report is similar to the findings of the current study in that pulmonary function is more severely impaired in patients with COVID-19 sepsis. 23, 24 In systemic and distant organs through bacteria entering the blood, but also through the release of a large number of pathogen-associated molecular patterns mediators, such as lipopolysaccharide, and so on. In addition, bacterial sepsis can further lead to the release of a large number of secondary damage-associated molecular patterns mediators, such as high mobility group box 1, which causes a larger and continuous inflammatory effect and finally leads to serious damage to distant organs, which is more likely to result in MODS and higher mortality. 27, 28 We also demonstrated more severe hypolymphocytosis in patients with COVID-19, suggesting that there may be more serious acquired immunosuppression. This phenomenon was in line with our current clinical observation that the course of COVID-19 is longer. The existence of secondary infection and lack of immune support at the later stages bring a high risk of rapid deterioration of the disease and possible death. Even in the case of more active breathing or ECMO support, the progression of the condition cannot be reversed, which is also consistent with the current survival results. 13, 14 We found that the proportion of corticosteroid therapy and ECMO support therapy were higher in the COVID-19 sepsis group, while the need of CRRT and invasive mechanical ventilation was less. The reason may be that the prominent manifestation in viral sepsis is more severe lung injury caused by local inflammation, while other organs are less affected. In order to control local inflammation and support severe respiratory failure, the use of corticosteroids and ECMO increased. [29] [30] [31] Bacterial sepsis is more likely to lead to a systemic inflammatory reaction and secondary organ damage, including renal dysfunction, which requires systemic blood purification therapy to alleviate inflammation and improve organ damage, including kidney damage. At the same time, as secondary organ damage progresses, there are additional concerns about the use of ECMO, which is primarily represented by cardiopulmonary support. 32 Invasive respiratory support as a treatment for severe respiratory infectious disease, but the establishment of artificial airways for invasive mechanical ventilation is more likely to lead to the spread of the virus, which limits the use of ventilators. The emergence of a large number of patients with COVID-19 in a short term may also be one of the reasons for the lack of medical resources, including ventilators.

Lin For this, the first concern is whether the 2019-nCoV is more specific in attacking the lungs. There have been some experimental studies on the loading of angiotensin converting enzyme-2 (ACE-2, a common receptor for viral invasion of coronaviruses and 2019-nCoV) in cells of different organs. Roca-Ho 6 found that the heart and pancreatic cells had the highest expression of ACE-2, but a lower level in the lung. In a human study, Guo et al. 7 found that patients with chronic pulmonary fibrosis had high expression of ACE-2 at the pulmonary artery, which could be further enhanced by viral infection. However, this study has not done comparison with bacterial infection. Jambusaria 8 found that lipopolysaccharide (LPS) can also enhance lung ACE-2 expression in mice. As a result, so far there is no clear evidence of any special close association between lung ACE-2 expression and specificity of 2019-nCoV to the lung. The APACHE-II score consisted of several items. In this study, CrKP patients had more chronic underlying diseases, which means the contribution of lung injury score between two groups should be different, namely the lung injury score weight of COVID-19 would be greater than that of CrKP. This may be a possible reason for that even with the same APACHE-II score in both groups, more serious lung injury exists in the COVID-19 cases.

At present, there is also no clear evidence that 2019-nCoV has specific aggression against lymphatic tissue. Low lymphocyte count is a common phenomenon in all sepsis and can be attributed to the accelerated J o u r n a l P r e -p r o o f apoptosis of lymphocytes driven by inflammation. Moreover, glucocorticoids are extremely important inducers of accelerated apoptosis of lymphocytes, which has long been demonstrated. Since hormone therapy is commonly used in this study, it is believed that the lower lymphocyte counts shown in COVID-19

patients are ineluctably related to hormone therapy, which is also one of the reasons that hormone therapy has always been controversial.

Q4: Why the prognosis of COVID-19 with more severe immunosuppression is better than that of CrKP?

Lymphocyte count is an important component of immune function and is closely related to the prognosis of sepsis. Immunosuppression reduces the body's ability to clear pathogens and leads to repeated infections. On the other hand, immunosuppression can also increase the body's tolerance to charge pathogens and reduce the damage caused by inflammatory response. In fact, no matter pathogens or immune suppression themselves will not cause direct damage to the body. What causes direct damage is the drastic inflammation. 9 It is a common fact that patients with bacterial sepsis who survive the inflammatory response may benefit from immunosuppression to some extent. However, this benefit only prolongs the survival time in bacterial sepsis. If the immunosuppression is not reversed, the infection cannot be effectively controlled, and the final prognosis is still poor, even with a fatality rate of more than 70% in the 4 th years. 3 COVID-19

appears to be different. Although immunosuppression also prevents pathogen clearance and there is no clear and effective antiviral drug for its management, it seems that as long as the patients can survive the deterioration phase, even if the virus cannot be completely cleared, a relatively good prognosis can be obtained. Whether this characteristic of 2019-nCoV infection is related to the so called "self-limiting" ability as many other viruses is unclear and deserves further exploration. However, research reports 10, 11 found that in the so-called "cured patients" of COVID-19, about 70% will be left with symptoms of mental disorders, fatigue weakness, etc., which are very similar to the PICS manifestation. The final outcome of these patients is difficult to evaluate right now. So, saying "prognosis of COVID-19 is better than CrKP" seems too early, which may be limited by the short-term observation.

We referred severe COVID-19 as sepsis caused by viral infection because it shares all the pathological and clinical features of sepsis as bacterial infection: systemic inflammatory response, immunosuppression, damage or failure of multiple systems and organs, and chronic damage in some patients. [12] [13] [14] Although there is a national standard for "severe COVID-19", it should be noted that both the government and hospitals attach great importance to 2019-nCoV infection and COVID-19. These patients are endowed with the most positive attitudes and the most perfect medical conditions that are not available to CrKP patients or other sepsis patients. This difference is bound to have a potential impact on the standard formulation, ICU admission timing, treatment methods, and prognosis between the two groups of patients. I suspect that most J o u r n a l P r e -p r o o f of true sepsis induced by COVID-19 is more likely to occur during its sustained progression or sudden deterioration other than in the early phase. Unfortunately, this study did not provide continuous data of these cases or autopsy data on deaths, which should be the most convincing evidence to distinguish the differences of sepsis induced by severe COVID-19 from by CrKP.

The third international consensus definitions for sepsis and septic shock (Sepsis-3)

Epidemiology and immune pathogenesis of viral sepsis

Viral sepsis in children

A novel coronavirus from patients with pneumonia in China

Real-time updates: national outbreak map of new coronary virus pneumonia

Risk factors of healthcare workers with corona virus disease 2019: a retrospective cohort study in a designated hospital of Wuhan in China

SARS-CoV-2 and viral sepsis: observations and hypotheses. The Lancet

Biomarkers of inflammation and the etiology of sepsis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Hypothesis for potential pathogenesis of SARS-CoV-2 infection--a review of immune changes in patients with viral pneumonia

COVID-19: consider cytokine storm syndromes and immunosuppression

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of coronavirus disease 2019 in China

National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7)

Persistent lymphopenia after diagnosis of COVID-19 predicts acute respiratory distress syndrome: A retrospective cohort study

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Human pulmonary endothelial cell permeability after exposure to LPS-stimulated leukocyte supernatants derived from patients with early sepsis

Bloodstream infections among carriers of carbapenem-resistant Klebsiella pneumoniae: etiology, incidence and predictors

COVID-19 versus non-COVID-19 acute respiratory distress syndrome: comparison of demographics, physiologic parameters, inflammatory biomarkers, and clinical outcomes

Comparative study of acute lung injury in COVID-19 and non-COVID-19 patients

Multiple organ infection and the pathogenesis of SARS

Pure viral sepsis secondary to community-acquired pneumonia in adults: risk and prognostic factors

Targeting HMGB1 in the treatment of sepsis

Genoan Klebsiella pneumoniae research group. Epidemiology, management, and outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in hospitals within the same endemic metropolitan area

On the use of corticosteroids for 2019-nCoV pneumonia

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Liver injury in COVID-19: management and challenges

Extracorporeal membrane oxygenation for septic shock

Chronic critical illness and the persistent inflammation, immunosuppression, and catabolism syndrome

Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome

Sepsis-induced immune dysfunction: can immune therapies reduce mortality

Positive RT-PCR test results in patients recovered from COVID-19

Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients

Characterization of ACE and ACE2 expression within different organs of the NOD mouse

Single-cell RNA analysis on ACE2 expression provides insights into SARS-CoV-2 potential entry into the bloodstream and heart injury

Endothelial heterogeneity across distinct vascular beds during homeostasis and inflammation

In fatal COVID-19, the immune response can control the virus but kill the patient

Sequelae in adults at 6 months after COVID-19 infection

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Autopsy of COVID-19 victims in China

SARS-CoV-2 and viral sepsis: observations and hypotheses

The severe COVID-19: a sepsis induced by viral infection? And its immunomodulatory therapy